# Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/ > **Published:** 2026-06-19T12:37:42-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:25:11-04:00 > **Clinical Summary:** Explore synthetic ketamine analog regulation with DEA's temporary scheduling of 2-fluorodeschloroketamine under Schedule I controlled substances. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA schedulingcannabis legislation[medical cannabis access](https://cedclinic.com/medical-marijuana-card-reciprocity/) Clinical Summary The Drug Enforcement Administration (DEA) has temporarily placed 2-fluorodeschloroketamine (2-FDCK), a synthetic ketamine analog, into Schedule I controlled substances, effectively banning its manufacture, distribution, and possession without authorization. This action addresses the emerging abuse potential of designer drugs that chemically mimic controlled substances while circumventing existing regulations, a challenge that has complicated the legitimate clinical use of ketamine and related compounds in anesthesia and emerging psychiatric applications. The temporary scheduling provides a regulatory window for the DEA and Department of Health and Human Services to evaluate whether permanent scheduling is warranted, which could impact ongoing or future [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) involving ketamine analogs for treatment-resistant depression and other psychiatric conditions. Clinicians should be aware that such scheduling actions reflect broader regulatory scrutiny of the ketamine class and may influence the timeline and approval pathway for novel ketamine-based therapeutics currently in development. The practical takeaway for clinicians is to remain informed about evolving DEA scheduling of synthetic drug analogs, as these regulatory changes may affect access to legitimate ketamine treatments and inform discussions with patients about the legal and clinical landscape of emerging psychopharmacologic interventions. Clinical Perspective 🧠 The DEA’s emergency scheduling of 2-fluorodeschloroketamine (2-FDCK), a designer ketamine analog, reflects the ongoing challenge of synthetic drug proliferation outpacing regulatory response and highlights the clinical relevance of emerging substances in managing substance use disorders and psychiatric emergencies. Clinicians should be aware that 2-FDCK and similar ketamine analogs may produce effects comparable to ketamine or phencyclidine, potentially presenting with dissociative, anesthetic, and sympathomimetic properties that complicate acute management and diagnosis in emergency and psychiatric settings. The temporary scheduling indicates formal recognition of [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) concern, yet the lag between emergence in illicit markets and regulatory action means providers may encounter patients with exposure to novel dissociative agents before comprehensive safety data becomes available. Complicating clinical assessment is the reality that street-level identification of specific analogs is unreliable, urine drug screens 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Temporary+Placement+of+2-Fluorodeschloroketamine+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F22%2F2026-10253%2Fschedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F22%2F2026-10253%2Fschedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Temporary+Placement+of+2-Fluorodeschloroketamine+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F22%2F2026-10253%2Fschedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - [Schedules of Controlled Substances: Placement of Diphenidine in Schedule I](https://cedclinic.com/dea-synthetic-dissociative-scheduling-diphenidine-schedule-i/) - [Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act](https://cedclinic.com/dea-scheduling-benzodiazepine-analogs-schedule-i/) - [Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://cedclinic.com/temporary-scheduling-novel-benzodiazepines-bromazolam-update/) 📰 Source: [https://www.federalregister.gov/documents/2026/05/22/2026-10253/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i](https://www.federalregister.gov/documents/2026/05/22/2026-10253/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I Detailed analysis of the DEA’s temporary scheduling of 2-fluorodeschloroketamine and its regulatory implications. Read More [Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://cedclinic.com/temporary-scheduling-novel-benzodiazepines-bromazolam-update/) Explore the DEA’s approach to temporary scheduling with bromazolam as a case study in synthetic drug regulation. [Explore Article](https://cedclinic.com/temporary-scheduling-novel-benzodiazepines-bromazolam-update/) [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) Insights into the scheduling of synthetic cannabinoids and regulatory trends affecting emerging substances. [Learn More](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).